To evaluate how often beta-blockers were started after acute myocardial infarction (AMI) in nursing home (NH) residents who previously did not use these drugs and to evaluate which factors were associated with post-AMI use of beta-blockers. DESIGN: Retrospective cohort using linked national Minimum Data Set assessments; Online Survey, Certification and Reporting records; and Medicare claims. SETTING: U.S. NHs. PARTICIPANTS: National cohort of 15,720 residents aged 65 and older who were hospitalized for AMI between May 2007 and March 2010, had not taken beta-blockers for at least 4 months before their AMI, and survived 14 days or longer after NH readmission. MEASUREMENTS: The outcome was beta-blocker initiation within 30 days of NH readmission. RESULTS: Fifty-seven percent (n = 8,953) of residents initiated a beta-blocker after AMI. After covariate adjustment, use of beta-blockers was less in older residents (ranging from odds ratio (OR) = 0.89, 95% confidence interval (CI) = 0.79-1.00 for aged 75-84 to OR = 0.65, 95% CI = 0.54-0.79 for ≥95 vs 65-74) and less in residents with higher levels of functional impairment (dependent or totally dependent vs independent to limited assistance: OR = 0.84, 95% CI = 0.75-0.94) and medication use (≥15 vs ≤10 medications: OR = 0.89, 95% CI = 0.80-0.99). A wide variety of resident and NH characteristics were not associated with beta-blocker use, including sex, cognitive function, comorbidity burden, and NH ownership. CONCLUSION: Almost half of older NH residents in the United States do not initiate a beta-blocker after AMI. The absence of observed factors that strongly predict beta-blocker use may indicate a lack of consensus on how to manage older NH residents, suggesting the need to develop and disseminate thoughtful practice standards.
O ne and one-half million older Americans live in nursing homes (NHs) and more than 50% of NH residents have cardiac disease. 1 NH residents are rarely included in randomized clinical trials (RCTs) used to inform practice guidelines for common conditions such as acute myocardial infarction (AMI). 2 The result is a profound lack of evidence to guide treatment decisions for older NH residents for whom the potential benefits of some interventions, such as beta-blocker therapy, may be counterbalanced by adverse effects to which older adults are particularly susceptible. 2 According to the 2013 American College of Cardiology Foundation/American Heart Association guidelines, oral beta-blocker therapy should be initiated for all individuals within 24 hours after AMI and continued for at least 3 years, in the absence of contraindications. [3] [4] [5] Beta-blockers are a mainstay of secondary prevention after hospitalization. RCTs that have demonstrated that the long-term use of beta-blockers after AMI substantially reduces mortality in individuals younger than 75 support the guideline recommendations. [6] [7] [8] [9] Observational studies have extended these findings to even older adults. Many studies report a mortality benefit in community-dwelling people aged 85 and older.
Data from community-dwelling older adults have shown that use of beta-blockers after AMI decreases with increasing age. 13, 14 Studies of community-dwelling individuals have also presented conflicting data on whether functional limitations and geriatric syndromes are associated with even lower rates of beta-blocker use, 13, 14 but much less is known about use of these agents in older NH residents, who often have different clinical characteristics and systems of care than their community-dwelling counterparts. A handful of studies on this topic conducted using data from the 1990s and in small, selected populations found low use of beta-blockers in NHs. [15] [16] [17] [18] [19] These studies have important limitations that hinder understanding of current patterns of beta-blocker use. Because these studies were done using older data and selected samples, the generalizability to the current national population of NH residents in the United States is unclear. Furthermore, little evidence is available to determine whether prescribing practices have changed in conjunction with general improvements in adherence to guideline recommendations related to ischemic heart disease in the United States. Last, the extent to which previously observed rates of betablocker use are due to the continuation of beta-blocker therapy from before AMI (prevalent use) or represent new prescribing choices after AMI is uncertain. Understanding recent prescribing practices in the NH setting is essential for identifying gaps in the quality of care and corresponding high-leverage points to address gaps.
Therefore, the objective of this study was to describe the epidemiology of beta-blocker use after AMI in a national sample of U.S. NHs. Individuals who were nonusers of betablockers were focused on to understand how NH prescribers respond to widely accepted clinical practice guidelines that recommend initiating a beta-blocker after AMI.
METHODS

Data Sources
Using national Medicare data, denominator (eligibility) information, Part A inpatient hospital claims, Part D prescription drug claims, and Minimum Data Set (MDS) 2.0 data for all fee-for-service beneficiaries from 2007 to 2010 who were eligible for inclusion were linked. The MDS is a comprehensive clinical assessment instrument used to document the health status of NH residents and included demographic and medical information and assessments of functional, psychological, and cognitive abilities. 20, 21 The Centers for Medicare and Medicaid Services requires that each certified U.S. NH conduct an MDS assessment of all residents on admission, quarterly thereafter, and with significant changes in clinical condition. 22 Online Survey Certification and Reporting (OSCAR) data were used for facility-level information, including NH characteristics and staffing levels. 23, 24 A previously validated residential history file algorithm was used to track the timing and location of health service use. 25 .
Study Population
This was a retrospective inception cohort study of a national cohort of long-stay NH residents without a history of AMI who were hospitalized for AMI, had not taken beta-blockers for at least 4 months before their AMI, and were readmitted to a U.S. NH directly after hospital discharge between May 1, 2007, and December 31, 2010 ( Figure 1 ). The final sample consisted of 15,720 NH residents admitted to 8,349 NHs. Residents lived in all 50 U.S. states, the District of Columbia, Puerto Rico, and the Virgin Islands. Previous nonusers were selected to permit an evaluation of the decision to initiate beta-blockers after AMI, distinct from the decision to continue these agents in individuals who had already been taking them before their AMI. The analysis was restricted to residents aged 65 and older who were in a NH for 90 days or longer and then hospitalized for an AMI, defined as a principal diagnosis on a Part A claim (International Classification of Diseases, Ninth Revision, codes 410.0-410.9), between May 1, 2007, and March 31, 2010 . Participants were required to have been continuously enrolled Medicare fee-for-service beneficiaries and have had no prescription for beta-blockers in the 4 months before the index AMI hospitalization. After the AMI, residents must have been discharged to a NH and not enrolled in hospice. Individuals with multiple AMIs entered the study on their first AMI during the study period. Individuals for whom beta-blocker exposure could not be reliably ascertained after readmission to the NH were excluded, including individuals with lapses in use of Medicare Part D, individuals who died within 14 days of NH readmission, and individuals rehospitalized within 14 days of NH readmission. To maintain the study population of NH residents, those who left the NH to receive care in other settings shortly after admission were also excluded.
Measurement of Beta-Blocker Use
Oral beta-blockers were identified according to generic name in Medicare Part D prescription drug claims, which contain a complete history of drug dispensing for this population, including date dispensed, dose, route, and days' supply. Part D coverage is common in NHs, with approximately 81% of residents covered. 26 Beta-blockers considered in this study included orally administered formulations of acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, and timolol.
Two complementary approaches were used to ascertain beta-blocker exposure based on the initial NH care pathway (long-term care (LTC) or skilled nursing facility (SNF) care) after the index AMI hospitalization. Individuals admitted directly from hospital to NH for LTC were classified as beta-blocker users if there was at least one dispensing of a beta-blocker in Part D claims within the first 30 days after admission. In contrast, medication ascertainment required a different approach for people readmitted to the NH under the SNF care pathway. Many NH residents-even those there for long-term residential care-return from the hospital to the NH on this time-limited SNF pathway. Medicare Part A pays for this pathway, which covers additional services such as extra rehabilitative therapy and high-level nursing care. 27 While beneficiaries are receiving SNF care, medication purchases are covered under a single bundled payment. 27 Because of this, Part D claims are not generated while beneficiaries are on the SNF pathway, precluding direct observation of medication use. After completion of a defined period of SNF services (typically <1 month, maximum 100 days), beneficiaries who continue to reside in the NH revert back to the LTC pathway. 27, 28 At this point, those with Medicare Part D coverage again receive their medications through the Part D program.
Therefore, to evaluate post-AMI beta-blocker use in individuals who returned to the NH with the Medicare SNF benefit, whether these individuals used beta-blockers once they had transitioned from SNF care back to LTC and Part D claims were once again available was evaluated. To test whether this approach was valid, a separate validation study was conducted using prescription drug dispensing data from a large, national private NH chain (HCR ManorCare, Inc., Toledo, OH), in which complete drug dispensing data were available regardless of SNF or LTC status. Nearly all residents (>94%) in this post-AMI cohort continued taking beta-blockers after transition from SNF to LTC. This suggested that, in the main study cohort, it was reasonable to impute beta-blocker use in the early posthospitalization SNF period based on beta-blocker use after transition to LTC. Subsequently, this approach was used for individuals admitted to the NH for SNF services after the index AMI hospitalization (N = 11,283). Beta-blocker use was defined as any dispensing within 60 days of transition from SNF to LTC (period during which medications are covered under Medicare Part D). Sixty days was selected as a sufficiently long period to allow for depletion of beta-blocker supplies obtained through Part A billing during SNF care, thus requiring a Part D dispensing. It was not possible to determine whether a beta-blocker was started during the index hospitalization and therefore whether the NH physician was continuing a recommendation to prescribe or not prescribe the drug that the inpatient physician initiated. Regardless, the NH physician was involved in the prescribing decision at some level insofar as only medications filled after return to the NH were evaluated.
Measurement of Resident and NH Characteristics
Variables that could potentially predict beta-blocker use included demographic characteristics (age, sex, race) from Medicare enrollment files, concomitant medication use (e.g., calcium channel blockers, loop diuretics, opioid analgesics) from Part D claims, and comorbidities (e.g., asthma, chronic obstructive pulmonary disease, congestive heart failure) from Part A claims, all measured in the year before AMI. Part A claims were also used to document recent hospital course, severity of cardiovascular disease, and Elixhauser Comorbidity Index score.
29.
A number of MDS items have been structured into reliable, valid measures of resident functional status. [30] [31] [32] The level of functional impairment for each resident was estimated using the MDS activity of daily living (ADL) score documented in the assessment closest to the AMI date in the 90 days before AMI. This summary measure indicates degree of dependence on staff assistance in seven areas of ADL function (bed mobility, transfer, locomotion, dressing, eating, toilet use, personal hygiene) and ranges from 0 (no assistance required) to 28 (total dependence in ADL functioning). 33 Cognitive function was measured using the Cognitive Performance Scale; scores range from 0 (intact) to 6 (severe impairment). 31 Other geriatric syndromes and conditions (weight loss; falls; presence and frequency of pain; Changes in Health, End-Stage Disease, Signs, and Symptoms Scale (CHESS) score) were also measured in the MDS. The CHESS score is a measure of prognosis and health instability and has been validated as a proxy for frailty. 34, 35 Although an MDS assessment after the AMI hospitalization and before beta-blocker initiation might have been preferred to capture updated values of variables that the AMI hospitalization could have altered, the first assessment occurred after beta-blocker initiation in nearly all cases.
Facility characteristics and indicators of care quality were obtained from the most recent OSCAR survey before the acute AMI hospitalization, such as ownership (profit, nonprofit, government), total number of beds, and total direct care hours per day per resident.
It was hypothesized that poor functional status and cognition, frailty, and older age would be associated with lower rates of beta-blocker use. Pre-AMI medication use was included as a marker of a resident's clinically active conditions and risk of future clinical events (e.g., residents prescribed statins may be at higher perceived risk of future cardiovascular events).
Analytical Approach
Univariable associations between potential predictors and beta-blocker initiation were first evaluated using logistic regression to estimate odds ratios (ORs). A multilevel multivariable logistic regression model was used to test the hypothesis that certain individual and facility factors would be independently associated with beta-blocker prescribing for residents after AMI. 36 Because residents are clustered within NHs facilities, random intercepts for facilities were included in the model to ensure more-accurate standard errors. 37 Resident and facility characteristics were modeled as fixed effects. Multivariable analyses were adjusted for the full set of variables shown in (Tables 2  and 3) , plus additional variables listed in (Table S2) . Data were analyzed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and Stata version 14.0 (Stata Corp., College Station, TX).
The institutional review boards of Brown University; the University of California, San Francisco; and the San Francisco Veterans Affairs Health Care System approved the study protocol.
RESULTS
Residents readmitted to the NH after AMI had a mean age of 83; 29% were male, 82% were non-Hispanic white, and 72% returned to the NH on the Medicare SNF benefit ( Table 1, Table S1 ); 73% of the cohort required extensive or greater assistance with ADLs, and 82% had some degree of cognitive impairment. Seventy-one percent of residents had at three or more comorbidities. Of the 8,349 unique NHs that residents returned to after AMI, 73% were for profit, and 70% had 100 beds or more. The number of residents returning to each NH after AMI ranged from one to 22, with an average of two residents per NH.
Of the 15,720 residents in the study population, 8,953 (57%) initiated a beta-blocker after returning to the NH after AMI. The proportion of residents newly prescribed a beta-blocker remained stable in each year of the study period (56.8% in 2007, 57.3% in 2008, 56.6% in 2009, 57.2% in 2010; chi-square P = .90). A beta-blocker was dispensed to 60% of those who returned to the NH on the Medicare SNF benefit and 51% of those discharged directly to LTC. There was variation in beta-blocker use after AMI according to geographic region, ranging from 53.2% of residents in the South to 61.5% of residents in the Northeast. The most frequently prescribed beta-blockers were metoprolol (69%), carvedilol (25%), and atenolol (4%).
In univariable analyses, few factors were meaningfully associated with beta-blocker use (Table 2, Table 3,  Table S2 ). Residents aged 95 and older were less likely than those aged 65 to 74 to receive beta-blockers (OR = 0.68, 95% confidence interval (CI) = 0.59-0.78). A diagnosis of angina pectoris (OR = 0.33, 95% CI = 0.30-0.36) or unstable angina (OR 0.71, 95% CI = 0.64-0.79) in the year before AMI was predictive of not receiving beta-blockers. Residents who spent any time in a coronary care unit or intensive care unit during the AMI hospitalization were more likely to receive beta-blockers than those who did not (1-3 days: OR = 1.48, 95% CI = 1.37-1.60; ≥4 days: OR 1.60, 95% CI = 1.49-1.72).
Functional impairment before AMI was not predictive of beta-blocker use in univariable analyses, but in multivariable analyses, residents with severe functional impairment were less likely to receive beta-blockers after returning to the NH after AMI (OR = 0.84, 95% CI = 0.75-0.94). Although older age was already a significant predictor of beta-blocker nonuse in univariable analyses, the strength of the association increased in multivariable analyses. Sex, cognitive function, CHESS score, and Elixhauser Comorbidity Index were not independently associated with beta-blocker use (Tables 2 and  3 ). The broad set of NH characteristics examined was also not independently associated with beta-blocker use (Table S2) . When the analyses were stratified according to initial post-AMI type of NH care, the independent associations between predictors and beta-blocker initiation were similar for residents who returned to the NH through the SNF and LTC pathways of care (data not shown).
DISCUSSION
Forty-three percent of this national sample of older NH residents did not receive beta-blockers within 30 days of returning to the NH after AMI. Advanced age and measures of frailty and functional dependence in the NH population explained some of the variation in beta-blocker use, but few factors were strongly predictive of betablocker use.
The absence of characteristics that were strongly predictive of beta-blocker use may suggest a lack of clarity and consensus among providers about how to manage treatment for NH residents after AMI. Although younger adults and individuals who are typically included in clinical trials tolerate beta-blockers well, [38] [39] [40] few data are available about the tolerability of beta-blockers in individuals who are frail, physically impaired, multimorbid, or very advanced in age. Without such data, clinicians may have concerns about the safety of these drugs in vulnerable older adults, 38, [41] [42] [43] [44] although markers of frailty and vulnerability, such as CHESS score and ability to perform ADLs, were only weakly predictive in the models, and age was more strongly predictive. This suggests that providers are not heavily basing their treatment decisions on functional status or other markers of frailty. Instead, providers might have embraced a person-centered approach that respects individuals' and their families' preferences to determine who receives beta-blockers. These findings reveal an opportunity for future research to improve the evidence base for using beta-blockers after AMI in the NH setting.
Unstable angina (multivariable-adjusted OR = 0.57, 95% CI = 0.50-0.66) and angina pectoris (multivariableadjusted OR = 0.29, 95% CI = 0.26-0.34) at baseline were notable exceptions to the absence of strong associations with beta-blocker use. Because both conditions are symptomatic expressions of ischemic heart disease, it could be that many individuals with these preexisting diagnoses were previously considered for beta-blocker therapy and rejected (e.g., because of contraindications or intolerance) -that the decision not to prescribe beta-blockers had been made before the AMI and so was not affected by that event.
Prior studies performed in ambulatory populations have reported underuse of beta-blockers for secondary prevention after AMI. 3, 10, 12, 14, [45] [46] [47] [48] Studies performed in NH populations have also reported underuse. [15] [16] [17] [18] [19] Many of the estimates are similar to those of the current study even though the current study data were more recent. For example, one study using Cooperative Cardiovascular Project data from February 1994 through November 1995 to examine beta-blocker use in elderly Medicare beneficiaries discharged from acute care hospitals in the United States after AMI found that 50% were prescribed a beta-blocker at the time of discharge, an estimate similar to what is reported herein.
14 The similarity of their estimate to that of the current study, despite their younger and less-multimorbid study population, may have been due to the use of earlier data reflecting the in-process dissemination of evidence about beta-blocker use in older adults. It may also be due in part to the use of prescribing data, which may have overestimated beta-blocker receipt in those who were not actually dispensed a beta-blocker. The previous study 14 also reported qualitatively similar relationships between functional status and beta-blocker use, whereby older adults with worse functional status were less likely to receive beta-blockers after AMI. Using the same data as in that study, another study that isolated a subset of individuals admitted to the hospital from the NH who were "ideally eligible" to receive beta-blockers found that 43.8% of NH residents who were ideally eligible were prescribed beta-blockers. 16 In contrast, beta-blockers were prescribed to 61.5% of the ideally eligible communitydwelling cohort upon discharge. The current study confirms that more-recent nationwide prescribing practices are similar to those described in earlier cohort studies with stricter inclusion criteria.
This study has some limitations. First, aside from the validation cohort from HCR ManorCare, Inc., betablocker use was unobservable during the SNF stay in the NH. As a consequence, the use of beta-blockers for some NH residents receiving SNF care may have been misclassified, although the validation cohort from HCR ManorCare, Inc., for whom beta-blocker use during SNF stay was observable, suggests that the approach used to classify beta-blocker use will be accurate for all but a small minority of individuals. Second, the data were from 2007 to 2010, but given the lack of substantial changes in guidelines, guideline dissemination, or NH standards of practice, it is unlikely that prescribing practices have changed markedly in the intervening years. Third, the study was focused on people who were not using beta-blockers before AMI, so as to evaluate new prescribing decisions about these drugs. Because individuals who use beta-blockers before AMI are likely to continue these drugs after AMI, overall use of beta-blockers after AMI is likely to be higher, and it was not possible to compare the observed rates directly with those of other studies that combine incident and prevalent beta-blocker use. Also, the inclusion criteria that participants must have lived for at least 14 days after hospital discharge had potential to create selection bias, which could have enriched the population with more betablocker users, although it is likely that such bias would have been small. Fourth, individuals without Medicare fee-for-service coverage, those without Medicare Part D prescription drug insurance, and those with several others factors were excluded, although it is unlikely that insurance coverage has a major influence on use of these inexpensive and ubiquitous medications. Finally, although the data included measures of several potential contraindications to beta-blocker use, including obstructive lung disease and concurrent use of calcium channel blockers with atrioventricular node-blocking activity, the data sources were unable to robustly capture other contraindications such as symptomatic bradycardia or hypotension. In summary, many elderly NH residents do not receive beta-blockers after AMI. The absence of observed factors that strongly predict beta-blocker use may indicate a lack of consensus on how to manage NH residents with AMI. This is not surprising given the absence of evidence documenting the benefits and harms of beta-blockers in older NH residents, and the relatively low use may suggest ongoing concern about the balance of these benefits and harms. Given practical and ethical considerations, it is unlikely that any randomized controlled trials to study this question will be forthcoming. Rather, rigorous observational studies will be critical for developing an evidence base to evaluate the effectiveness, including mortality and rehospitalization, and potential adverse events, including functional outcomes, of beta-blockers in older NH residents.
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